Aerovate Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 20.41 million compared to USD 15.02 million a year ago. Basic loss per share from continuing operations was USD 0.74 compared to USD 0.61 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.75 USD | +0.83% | -1.36% | -3.89% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.89% | 625M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- AVTE Stock
- News Aerovate Therapeutics, Inc.
- Aerovate Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023